ReShape Lifesciences Inc (RSLS) News

Form 425 - Prospectuses and communications, business combinations

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update

Entered into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys...

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier...

Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”

CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vyome Therapeutics, a clinical-stage healthcare company...

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating...

ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier...